11:47 AM EST - Cardiome Pharma Corp. : and SteadyMed Ltd. today announced that the European Medicines Agency (EMA) has approved Cardiome’s request to review Trevyent® (treprostinil PatchPump) under the Centralised Authorisation Procedure drug review process. Cardiome Pharma Corp.
shares T.COM are trading down $0.04 at $10.96.
